IDEXX Laboratories stock gains as CoVetAI deal and new parasite tests bolster growth narrative

IDEXX Laboratories stock (ISIN US45168D1046) is trading around USD 504 on Nasdaq on September 17, 2026, after recent news on acquisitions and expanded parasite testing platforms reinforced the company’s growth story in veterinary diagnostics and software.

Acquisition of CoVetAI strengthens software offering

IDEXX Laboratories, Inc. announced that it acquired CoVetAI Inc., a fast-growing provider of AI-native ambient listening and clinical workflow software for veterinary practices, with the release dated September 16, 2026, according to IDEXX Laboratories.

Financial terms of the CoVetAI transaction were not disclosed, but the deal is positioned as a way to enhance veterinary workflow intelligence and integrate AI-based ambient listening into IDEXX’s practice management ecosystem, which for investors underlines a strategic push into higher-value software and services alongside traditional diagnostics.

Expanded Faecal Dx parasite testing boosts diagnostics menu

On September 17, 2026, IDEXX Laboratories announced that it is expanding its Faecal Dx antigen testing platform in the United Kingdom to include taeniid tapeworm detection, covering Taenia and Echinococcus species, according to Financial Times.

The company also extended its Fecal Dx antigen testing platform in France with Taenia and Echinococcus detection for reference laboratory customers, as outlined in a Business Wire release dated September 17, 2026, according to Business Wire.

These expanded panels add taeniid tapeworm detection at no additional cost for IDEXX Reference Laboratories customers, and positive results automatically trigger a follow-up RealPCR test for Echinococcus, according to the same Business Wire release, which meaningfully increases the depth of parasite screening in Europe for zoonotic risks and may drive incremental test volumes in the company’s diagnostic segment.

Market reaction and valuation context

As of the September 17, 2026 session, IDEXX Laboratories stock is quoted at around USD 504.51 on Nasdaq, with a day decline of 1.77 percent at 10:46 a.m. Eastern Time, based on exchange data reported by a major financial portal; trailing total returns as of September 17, 2026 show a year-to-date gain of 25.43 percent, versus an 11.39 percent rise in the S&P 500 index over the same period, according to the same portal.

Recent European market data showed IDEXX Laboratories closing at USD 513.62 on Nasdaq on September 16, 2026, up 0.57 percent for that session, while the stock’s five-day performance was slightly negative and its year-to-date performance was cited at about negative 0.30 percent in that specific local context, according to Zonebourse.

The discrepancy between the year-to-date return of 25.43 percent reported for IDEXX on Nasdaq as of September 17, 2026 and the slightly negative year-to-date figure in the European overview underscores how different data snapshots and calculation bases can affect perceived performance, but both sources illustrate that IDEXX Laboratories stock has delivered stronger returns than broader benchmarks over longer horizons while experiencing short-term volatility.

Growth expectations and implied upside

Analyst commentary published on September 17, 2026 outlines a narrative in which IDEXX Laboratories is projected to reach USD 5.7 billion in revenue and USD 1.5 billion in earnings by 2029, which implies approximately 8.7 percent annual revenue growth and an earnings increase of about USD 0.4 billion from USD 1.1 billion in earnings today, according to a detailed valuation analysis from Yahoo Finance.

The same analysis derives a fair value estimate of USD 709.14 per share for IDEXX Laboratories, representing a 38 percent upside relative to its current trading price at the time of the report, and ties the valuation case directly to sustained growth in diagnostics and expanded zoonosis testing menus, which include parasite and pathogen detection offerings.

Separately, a Barclays analyst action dated August 11, 2026 maintained an Overweight rating on IDEXX while lowering the price target from USD 800 to USD 710, signaling continued positive stance on the stock but with moderated expectations, according to analyst action data displayed on Yahoo Finance.

Risks and competitive landscape

The valuation analysis on IDEXX notes that the revenue and earnings trajectories to 2029 depend on the company achieving near-9 percent average annual revenue growth and expanding margins sufficiently to grow earnings by roughly 36 percent from USD 1.1 billion to USD 1.5 billion, according to Yahoo Finance, which introduces execution risk if adoption of new tests or software lags these projections.

For investors, the main counter-factors to the bullish thesis include the need for continuing investment in R&D and digital workflow integration, competition in the veterinary diagnostics and software space, and sensitivity of testing volumes to macroeconomic conditions in pet healthcare, all of which could affect whether IDEXX reaches the projected USD 5.7 billion revenue and USD 1.5 billion earnings levels by 2029.

Stock price and trading data

IDEXX Laboratories stock trades on Nasdaq under the ticker IDXX, with the reference price around USD 504.51 as of September 17, 2026 in intraday trading, and a previous closing level of approximately USD 513.62 on September 16, 2026, while recent data indicate a market capitalization near USD 40 billion based on Morningstar-provided figures displayed in a market overview.

More news and analyses on IDEXX Laboratories stock